CJC-1295: GHRH Analog Mechanism, Research & Scientific Overview

Key Points

• CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), comprising the first 29 amino acids with strategic modifications
• Two primary forms exist: CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC (also called Modified GRF 1-29)
• The DAC modification enables binding to serum albumin, extending plasma half-life from minutes to approximately 6-8 days
• Primary mechanism involves selective activation of GHRH receptors on pituitary somatotrophs
• Research suggests synergistic effects when combined with growth hormone secretagogues (GHS) such as Ipamorelin
• Not approved by FDA for any therapeutic application

Table of Contents

1. Introduction
2. Molecular Structure
3. CJC-1295 with DAC vs Without DAC
4. Mechanism of Action
5. Research Overview
6. Combination with GHRP
7. Stability & Handling
8. Research Limitations
9. Conclusion
10. References

Introduction

Growth hormone-releasing hormone (GHRH), also known as somatoliberin or somatocrinin, is a 44-amino acid hypothalamic peptide that serves as the primary physiological stimulator of growth hormone (GH) secretion from the anterior pituitary gland. Since its isolation and characterization in the early 1980s, researchers have sought to develop analogs with improved pharmacokinetic profiles and enhanced stability.

CJC-1295 emerged from this pursuit as a modified GHRH analog designed to overcome the rapid enzymatic degradation that limits native GHRH's utility in research applications. The peptide represents the bioactive N-terminal fragment of GHRH (amino acids 1-29) with specific amino acid substitutions that confer resistance to proteolytic degradation, particularly by dipeptidyl peptidase-IV (DPP-IV).

This article provides a comprehensive scientific examination of CJC-1295, presenting documented research findings and mechanistic data without therapeutic claims. Understanding both forms of CJC-1295—with and without Drug Affinity Complex—is essential for researchers working in the fields of endocrinology, peptide pharmacology, and growth hormone axis regulation.

Molecular Structure

Native GHRH Background

Human GHRH is synthesized as a 108-amino acid preprohormone and processed to yield the mature 44-amino acid peptide. However, the biological activity resides primarily in the first 29 amino acids (GHRH 1-29), with the C-terminal region contributing to stability rather than receptor activation.

Native GHRH (1-44) Sequence:

H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2

CJC-1295 Modifications

CJC-1295 incorporates specific amino acid substitutions at positions 2, 8, 15, and 27 to enhance stability:

Molecular Properties

The Modified GRF 1-29 Sequence

Position:   1    2    3    4    5    6    7    8    9    10
Sequence:   Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-

Position:   11   12   13   14   15   16   17   18   19   20
Sequence:   Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-

Position:   21   22   23   24   25   26   27   28   29
Sequence:   Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2

CJC-1295 with DAC vs Without DAC

Understanding the Critical Distinction

The two forms of CJC-1295 differ substantially in their pharmacokinetic profiles, and this distinction is fundamental for research design and interpretation.

CJC-1295 Without DAC (Modified GRF 1-29)

Characteristics:

• Half-life: Approximately 30 minutes
• Mechanism: Direct GHRH receptor activation without albumin binding
• GH release pattern: Pulsatile, mimicking physiological secretion
• Peak GH levels: Achieved within 30-60 minutes post-administration

Pharmacokinetic Profile: The absence of the DAC moiety means the peptide relies solely on its amino acid substitutions for stability enhancement. While significantly more stable than native GHRH (half-life ~10 minutes), it remains subject to relatively rapid clearance.

CJC-1295 With DAC

Drug Affinity Complex Technology: The DAC moiety consists of a reactive maleimidoproprionic acid (MPA) group attached to a lysine residue at position 30. This modification enables covalent binding to serum albumin following administration.

Characteristics:

• Half-life: Approximately 6-8 days
• Mechanism: Albumin conjugation creates a circulating reservoir
• GH release pattern: Sustained elevation rather than discrete pulses
• Bioavailability: Markedly extended due to albumin protection

Comparative Analysis

Research Implications

The choice between variants depends on experimental objectives:

CJC-1295 Without DAC:

• Preferred for studying acute GH axis responses
• Better mimics natural GH pulsatility
• Allows precise timing of GH release studies
• Lower sustained hormone levels between administrations

CJC-1295 With DAC:

• Suited for chronic administration protocols
• Provides sustained IGF-1 elevation
• Simplifies long-term study logistics
• May produce more consistent steady-state effects

Mechanism of Action

GHRH Receptor Activation

CJC-1295 exerts its primary effects through selective binding to the growth hormone-releasing hormone receptor (GHRH-R), a G protein-coupled receptor (GPCR) expressed predominantly on pituitary somatotroph cells.

Receptor Binding and Signal Transduction:

1. Receptor Recognition: CJC-1295 binds to GHRH-R with high affinity (similar to native GHRH)
2. G-Protein Coupling: Receptor activation triggers Gs protein dissociation
3. Adenylate Cyclase Activation: Gs-alpha subunit stimulates adenylate cyclase
4. cAMP Generation: Increased intracellular cyclic AMP levels
5. PKA Activation: cAMP activates protein kinase A
6. Gene Transcription: CREB phosphorylation enhances GH gene expression
7. GH Release: Calcium influx triggers secretory granule exocytosis

Downstream Effects

Growth Hormone Release:

• Direct stimulation of GH synthesis and secretion
• Amplitude modulation of GH pulses
• Somatotroph proliferation over chronic exposure

IGF-1 Axis Activation:

• Hepatic IGF-1 production stimulated by circulating GH
• IGF-1 mediates many GH-attributed effects
• IGF binding protein regulation

Metabolic Effects (Animal Studies):

• Enhanced lipid mobilization
• Altered glucose metabolism
• Protein anabolic effects
• Bone metabolism modulation

Interaction with Somatostatin

The GH axis operates through dual hypothalamic regulation:

• GHRH stimulates GH release
• Somatostatin (SRIF) inhibits GH release

CJC-1295's effects are subject to this regulatory interplay. Research demonstrates that somatostatin can suppress CJC-1295-induced GH release, maintaining physiological negative feedback despite exogenous GHRH analog administration.

Research Overview

Preclinical Studies

Initial Development and Characterization

ConjuChem Biotechnologies developed CJC-1295 as part of their Drug Affinity Complex platform. Early preclinical research established the pharmacokinetic advantages of the albumin-binding modification.

Jetté et al. (2005) demonstrated in animal models that DAC-conjugated GRF analogs showed dramatically extended half-lives compared to unconjugated peptides, with sustained GH elevation over days rather than hours.

Animal Model Research

Rodent Studies: Research in rat models has documented:

• Dose-dependent GH elevation
• Sustained IGF-1 increases
• Effects on body composition parameters
• Somatotroph responsiveness maintenance

Porcine Studies: Studies in swine models examined:

• Growth performance parameters
• Feed efficiency modifications
• Carcass composition changes
• Hormone axis feedback mechanisms

Human Research

Phase I/II Clinical Trials

Teichman et al. (2006) published results from early human trials examining CJC-1295 with DAC in healthy adult subjects:

Key Findings:

• Single subcutaneous doses (30-125 mcg/kg) produced sustained GH elevation
• IGF-1 levels increased 1.5 to 3-fold above baseline
• Effects persisted for 6-14 days post-administration
• Generally well-tolerated in short-term studies

Pharmacokinetic Data:

• Terminal half-life: 5.8-8.1 days
• Peak plasma concentrations: 6-8 hours post-injection
• Albumin binding confirmed in vivo

Growth Hormone Response Patterns

Research documented distinct response characteristics:

With DAC:

• Gradual GH elevation following administration
• Sustained plateau rather than discrete peaks
• IGF-1 elevation correlating with GH exposure
• Prolonged axis stimulation

Without DAC (Limited Human Data):

• Rapid GH pulse within 30-60 minutes
• Return to baseline within 2-3 hours
• Repeated administration produces repeated pulses
• More physiological secretion pattern

Research on GH Deficiency Models

Investigational research has explored CJC-1295 in contexts of GH axis dysfunction:

• Age-related GH decline models
• Hypothalamic-pituitary dysfunction
• GH secretagogue response studies
• Somatopause research

Metabolic Research

Studies have examined metabolic parameters:

Body Composition:

• Lean mass measurements
• Fat mass alterations
• Regional fat distribution

Metabolic Markers:

• Glucose homeostasis parameters
• Lipid profile changes
• Insulin sensitivity assessments

Combination with GHRP

Rationale for Combination Approaches

Growth hormone secretion is regulated by multiple hypothalamic and peripheral signals. Combining GHRH analogs with growth hormone-releasing peptides (GHRPs) or growth hormone secretagogues (GHS) targets complementary pathways.

Mechanistic Synergy:

• GHRH analogs (CJC-1295): Activate GHRH receptors, stimulate GH synthesis and release
• GHRPs/GHS: Activate ghrelin receptors (GHS-R1a), amplify GH pulse amplitude

CJC-1295 and Ipamorelin

Ipamorelin is a synthetic pentapeptide GHS with selectivity for GH release without significant effects on cortisol or prolactin. The combination has received particular research attention.

Ipamorelin Characteristics:

• Molecular formula: C38H49N9O5
• Molecular weight: 711.85 Da
• Half-life: ~2 hours
• Selectivity: GH-specific, minimal ACTH/cortisol effects

Combination Research Findings:

Studies examining concurrent administration suggest:

• Enhanced GH pulse amplitude compared to either agent alone
• Maintained pulsatile GH secretion (with CJC-1295 no DAC)
• Potential for reduced individual dosing requirements
• Preserved GH axis feedback mechanisms

Synergy Mechanisms

Research Protocol Considerations

Studies examining combination approaches typically address:

• Timing of administration (simultaneous vs. sequential)
• Dose optimization for each component
• Duration of combined treatment protocols
• Endpoint selection and measurement timing
• Adverse event monitoring with combination use

Other GHRP Combinations

Research has also examined CJC-1295 with other secretagogues:

GHRP-2:

• More potent GH release than Ipamorelin
• Stimulates cortisol, prolactin (less selective)
• Increases appetite via ghrelin pathway

GHRP-6:

• Similar profile to GHRP-2
• Notable hunger stimulation
• Established research history

Hexarelin:

• High potency GH release
• Cardiac research applications
• Desensitization concerns with chronic use

Stability & Handling

Storage Recommendations

Reconstitution Guidelines

Materials Required:

• Sterile bacteriostatic water or sterile saline
• Sterile syringes and needles
• Alcohol swabs for aseptic technique
• Sterile vials for aliquoting

Protocol:

1. Equilibration: Allow lyophilized vial to reach room temperature (15-20 minutes)
2. Solvent Addition: Add sterile water slowly along vial wall
3. Dissolution: Allow peptide to dissolve without vortexing (gentle swirling acceptable)
4. Inspection: Confirm complete dissolution and absence of particulates
5. Aliquoting: Prepare single-use aliquots to minimize freeze-thaw cycles
6. Documentation: Record concentration, date, and storage conditions

Concentration Calculations:

For a 2 mg vial reconstituted with 2 mL sterile water:

• Concentration = 1 mg/mL = 1000 mcg/mL
• For 100 mcg dose: 0.1 mL

Stability Considerations

Factors Affecting Stability:

1. Temperature: Higher temperatures accelerate degradation
2. pH: Optimal stability at pH 6.0-7.5
3. Light Exposure: Protect from direct light, especially UV
4. Oxidation: Minimize exposure to atmospheric oxygen
5. Freeze-Thaw Cycles: Each cycle reduces potency
6. Proteases: Ensure sterile handling to prevent contamination

Quality Indicators:

• Turbidity indicates potential aggregation or contamination
• Color changes suggest oxidation or degradation
• Particulate matter indicates instability

DAC-Specific Considerations

CJC-1295 with DAC presents additional stability considerations:

• The MPA group is reactive and can undergo hydrolysis
• Protect from extended aqueous storage prior to use
• Fresh reconstitution preferred for research applications
• Monitor for aggregation with albumin-containing solutions

Research Limitations

Evidence Quality Assessment

Critical evaluation reveals significant limitations in the current evidence base:

Translation Concerns

1. Species Differences: GH axis regulation varies across species
2. Dose Extrapolation: Animal-to-human dose conversion uncertain
3. Endpoint Relevance: Surrogate markers may not predict clinical outcomes
4. Duration Effects: Long-term consequences inadequately characterized

Study Design Limitations

Sample Sizes:

• Most human studies involve small cohorts (n < 50)
• Statistical power for secondary endpoints often insufficient
• Subgroup analyses limited by participant numbers

Control Groups:

• Placebo-controlled data limited for some outcomes
• Active comparator studies scarce
• Blinding challenges in injection studies

Publication Bias:

• Positive results more likely published
• Negative or null findings underrepresented
• Industry-sponsored research predominates

Safety Considerations

Short-term Observations:

• Injection site reactions (erythema, induration)
• Transient flushing or warmth
• Headache reported in some studies
• Water retention noted with sustained GH elevation

Theoretical Long-term Concerns:

• Sustained IGF-1 elevation and neoplasia risk
• Glucose homeostasis alterations
• Acromegaloid effects with chronic supraphysiological exposure
• Antibody development against peptide or albumin conjugate

Data Gaps:

• Long-term safety profiles not established
• Pediatric population data absent
• Elderly population specific data limited
• Drug interaction studies incomplete

Regulatory Status

FDA Status:

• Not approved for any therapeutic indication
• Investigational compound status
• Not available by prescription

International Classification:

• WADA prohibited list (S2: Peptide Hormones, Growth Factors)
• Controlled or restricted in various jurisdictions
• Research-use-only designation in most contexts

Areas Requiring Further Investigation

• Optimal dosing regimens for various research applications
• Long-term safety and efficacy data
• Head-to-head comparisons with other GH axis modulators
• Biomarker development for response prediction
• Mechanistic studies on tissue-specific effects
• Combination therapy optimization
• Special population considerations

Conclusion

CJC-1295 represents a significant advancement in GHRH analog development, offering researchers improved pharmacokinetic profiles compared to native GHRH. The availability of two distinct forms—with and without Drug Affinity Complex—provides flexibility for different experimental paradigms, from acute pulsatile GH studies to chronic sustained exposure protocols.

The molecular modifications conferring DPP-IV resistance and, in the DAC variant, albumin binding capability, demonstrate sophisticated peptide engineering approaches. Understanding these structural features is essential for interpreting research findings and designing appropriate experimental protocols.

Combination approaches, particularly with Ipamorelin, leverage complementary mechanisms to amplify GH axis stimulation. This synergistic potential has generated substantial research interest, though optimal protocols remain under investigation.

Current evidence, while promising in preclinical and early clinical contexts, carries important limitations. The predominance of small, short-term studies, coupled with regulatory restrictions, leaves significant knowledge gaps regarding long-term effects and clinical applicability. Researchers must approach the literature critically, recognizing that progression to approved therapeutic status would require substantially more rigorous clinical development than currently exists.

CJC-1295 remains a valuable research tool for investigating GH axis physiology, but translation to clinical application awaits further systematic investigation and regulatory evaluation.

References

1. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536

2. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286

3. Alba M, Fintini D, Sagavio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006

4. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702

5. Sackmann-Sala L, Ding J, Frohman LA, et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein changes in humans. Growth Horm IGF Res. 2009;19(3):267-274. doi:10.1016/j.ghir.2008.11.003

6. Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316-1329. doi:10.1007/s000180050257

7. Veldhuis JD, Iranmanesh A, Ho KK, et al. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab. 1991;72(1):51-59. doi:10.1210/jcem-72-1-51

8. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552

9. Frohman LA, Downs TR, Chomczynski P. Regulation of growth hormone secretion. Front Neuroendocrinol. 1992;13(4):344-405. PMID: 1281124

10. Mayo KE, Miller T, DeAlmeida V, et al. Regulation of the pituitary somatotroph cell by GHRH and its receptor. Recent Prog Horm Res. 2000;55:237-266. PMID: 11036939

11. Thorner MO, Vance ML, Laws ER Jr, et al. The anterior pituitary. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. Williams Textbook of Endocrinology. 9th ed. Philadelphia: WB Saunders; 1998:249-340.

12. Ghigo E, Arvat E, Camanni F. Orally active growth hormone secretagogues: state of the art and clinical perspectives. Ann Med. 1998;30(2):159-168. doi:10.3109/07853899809005849

13. Anderson NB, Malmlöf K. The effect of chronic combination treatment with Growth Hormone Releasing Peptide-2 and Growth Hormone Releasing Hormone on GH and IGF-1 secretion in rats. Growth Horm IGF Res. 2000;10(5):261-267. doi:10.1054/ghir.2000.0161

14. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-797. doi:10.1210/edrv.19.6.0353

15. Hartman ML, Farello G, Pezzoli SS, et al. Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men. J Clin Endocrinol Metab. 1992;74(6):1378-1384. doi:10.1210/jcem.74.6.1592886

16. Pandya N, DeMott-Friberg R, Bowers CY, et al. Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. J Clin Endocrinol Metab. 1998;83(4):1186-1189. doi:10.1210/jcem.83.4.4717

17. Veldhuis JD, Patrie JT, Frick K, et al. Administration of recombinant human GHRH-1,44-amide for 3 months reduces abdominal visceral fat mass and increases physical performance measures in postmenopausal women. Eur J Endocrinol. 2005;153(5):669-677. doi:10.1530/eje.1.02019

18. Copinschi G, Van Onderbergen A, L'Hermite-Balériaux M, et al. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. J Clin Endocrinol Metab. 1996;81(8):2776-2782. doi:10.1210/jcem.81.8.8768828